# An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

> **NCT00597116** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 25 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Vandetanib

## Key facts

- **NCT ID:** NCT00597116
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Recruitment stopped according to early stopping rule (by protocol)
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00597116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00597116, "An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00597116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*